Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

Structure Therapeutics (GPCR) has fallen sharply, down 30.7% over the past month to $35.00, leaving shares 62.7% below their 52-week high with an RSI of 17 and trading 35.8% below the 200-day moving average. The clinical-stage biotech, which develops oral therapeutics for chronic diseases, reported no revenue in the June 2026 quarter with a net loss of $106.2M, wider than the prior quarter's $76.2M loss, and has missed EPS estimates in three of the last four quarters, including a 25.6% miss in the most recent period. The company holds $272.6M in cash against minimal debt of $6.2M, though it burned $120.1M in operating cash flow last quarter. Recent news flow includes a 3.3% mean body-weight reduction from a single dose of ACCG-2671 in a Phase 1/2a trial, alongside reiterated bullish ratings from Citizens ($110 target) and Clear Street ($99 target), versus an analyst consensus target of $105.78.